Fig. 4: Sitagliptin downregulates NFκB pathway during liver inflammation in STZ-induced diabetic mice. | Cell Death Discovery

Fig. 4: Sitagliptin downregulates NFκB pathway during liver inflammation in STZ-induced diabetic mice.

From: Dipeptidyl peptidase-4 (DPP4) inhibitor sitagliptin alleviates liver inflammation of diabetic mice by acting as a ROS scavenger and inhibiting the NFκB pathway

Fig. 4

A RNA-seq heatmap of the expression of mentioned genes in liver tissues of STZ-induced diabetic mice. B Real-time PCR analysis of Cxcl10, Ccl2, Tnfα, Col1, and Col3 levels in diabetic mice with or without sitagliptin treatment. C Gene signatures for NFκB activation (HALLMARK_TNFA_SIGNALING_VIA_NFKB) were enriched within STZ group comparing with STZ + SITA group. D F4/80 staining of liver tissues (scale bar 100 and 200 μm) in STZ-induced diabetic mice with or without sitagliptin treatment. E Western blottings and quantitative analysis of the effects of sitagliptin on the protein levels of DPP4, IKKα, p-P65S536, P65, IKBα, and p-IKBαS36 in mice liver tissues (n = 5 mice per group). The results are presented as mean ± SEM of three independent experiments; *P < 0.05, **P < 0.01, ***P < 0.001.

Back to article page